Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 56, 45-62

Metabolic Syndrome: A Clinical and Molecular Perspective


Metabolic Syndrome: A Clinical and Molecular Perspective

David E Moller et al. Annu Rev Med.


The metabolic syndrome is a cluster of interrelated common clinical disorders, including obesity, insulin resistance, glucose intolerance, hypertension, and dyslipidemia (hypertriglyceridemia and low HDL cholesterol levels). According to recently defined criteria, the metabolic syndrome is prevalent and is associated with a greater risk of atherosclerotic cardiovascular disease than any of its individual components. Primary defects in energy balance that produce obesity (and visceral adiposity in particular) are sufficient to drive all aspects of the syndrome. Increased free fatty acids and lipid accumulation in certain organs are mediators of insulin resistance. Obesity also leads to a proinflammatory and prothrombotic state that potentiates atherosclerosis. Pathways leading directly from adiposity to the genesis of dyslipidemia and hypertension have been elucidated. Recent knowledge implies a role for fat-derived "adipokines," including TNF alpha and adiponectin, as pathogenic contributors or protective factors. Current therapies include diet and exercise as well as agents indicated for the treatment of individual components of the syndrome. Future therapies may accrue from the aggressive pursuit of newer molecular drug targets that have the potential to prevent or treat multiple aspects of the metabolic syndrome.

Similar articles

  • The Insulin Resistance Syndrome: Mechanisms of Clustering of Cardiovascular Risk
    JC Chan et al. Semin Vasc Med 2 (1), 45-57. PMID 16222595. - Review
    For more than a decade, insulin resistance has been proposed as the key linking factor for the metabolic syndrome disease cluster of glucose intolerance, hypertension, dy …
  • Management Issues in the Metabolic Syndrome
    PC Deedwania et al. J Assoc Physicians India 54, 797-810. PMID 17214277. - Review
    The metabolic syndrome or cardiovascular dysmetabolic syndrome is characterized by obesity, central obesity, insulin resistance, atherogenic dyslipidemia, and hypertensio …
  • Treatment of Metabolic Syndrome
    A Wagh et al. Expert Rev Cardiovasc Ther 2 (2), 213-28. PMID 15151470. - Review
    The metabolic syndrome is intended to identify patients who have increased risk of diabetes and/or a cardiac event due to the deleterious effects of weight gain, sedentar …
  • New Approach in the Treatment of T2DM and Metabolic Syndrome (Focus on a Novel Insulin Sensitizer)
    A Tjokroprawiro. Acta Med Indones 38 (3), 160-6. PMID 17119268. - Review
    Peroxisome Proliferator-Activate Receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily. The three PPARs (alpha, beta/delta, and gamma) …
  • Challenges Associated With Metabolic Syndrome
    SA Spinler. Pharmacotherapy 26 (12 Pt 2), 209S-217S. PMID 17125447. - Review
    Approximately 2500 Americans die from cardiovascular disease (CVD) each day. Each year, CVD claims more lives than the next four leading causes of death combined. Direct …
See all similar articles

Cited by 153 PubMed Central articles

See all "Cited by" articles

MeSH terms


LinkOut - more resources